J0717
J0717 – Injection, certolizumab pegol, 1 mg (code may be used for medicare when · NDC Crosswalk & Billing Units
HCPCS Level II J-code · Medicare Part B drug billing
J-code
● 4 NDCs crosswalked per 1 MG $3.444/unit ASP+6%
📋 J0717 summary
J0717 is a HCPCS Level II J-code used to bill certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the d..., billed per 1 MG. The number of billing units to report depends on the dose administered and the NDC/package billed — use the calculator below.
Brand names associated with J0717: Cimzia (2 Pack)*, Cimzia
Code J0717
Billing unit 1 MG Payment limit $3.444/unit NDC-Crosswalk 4
Quarter Q3 2026
RxCUI Atlas Trace the drug concept →
⚠ An NDC↔HCPCS crosswalk and a published payment limit do not guarantee payer coverage or payment. Always verify the current payer policy and claim format before billing.
🗂️ Key billing facts
HCPCS codeJ0717
DescriptorInjection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)
Billing unit1 MG
Payment limit / unit$3.444
Est. ASP / unit$3.249 est.
Mapped NDCs4
Data periodQ3 2026
Last updated2026-08-20
💊 About Certolizumab Injection DRUG GUIDE
Cimzia is used to treat several inflammatory conditions in adults: moderately to severely active Crohn's disease (in adults who haven't responded well to standard therapy), moderately to severely active rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, active non-radiographic axial spondyloarthritis with signs of inflammation, and moderate-to-severe plaque psoriasis in adults who need systemic treatment or phototherapy.Cimzia is also approved to treat active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older — one of its few pediatric uses.
Effectiveness for Crohn's disease in children and adolescents was not demonstrated in clinical study.
Clinical overview from our editorial drug guide for Certolizumab Injection. For billing reference, see the sections above.
🧾 Billing & reimbursement HCPCS · CMS · EFF. Q3 2026
📅 Payment limits effective Q3 2026 — from the CMS Medicare Part B Payment Limit File (revised quarterly).
Medicare payment limit / unit
$3.444
Est. ASP / unit
$3.249 est.
Est. after 2% sequester
$3.375
HCPCS dosage
1 MG
The CMS payment limit is the Medicare Part B drug allowance (ASP + 6%, statutory). After the 2% federal sequester the effective payment is ≈ ASP + 4.3%; estimated ASP = payment limit ÷ 1.06. Source: CMS Medicare Part B Payment Limit File (quarterly), Q3 2026.
Full HCPCS code details (official CMS record)
Long descriptionInjection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)
CoverageC — Carrier/MAC judgment
Pricing indicator51 — Drug — priced under the ASP methodology
Type of service1 — Medical care
BETOS-2O1E
ASC payment groupYY
Action codeN — No maintenance this year
Effective date2014-01-01
Date added2014-01-01
Source: CMS HCPCS Level II code file (imported via admin).
🧮 Dosing & billing-units calculator HCPCS UNITS
One billing unit of J0717 = 1 mg. Enter a regimen to convert dose → billing units and project a full course.
Billing units = dose ÷ HCPCS unit size. Most payers require whole units — round per the payer's policy. “Est. Medicare pay” uses the current payment limit. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (JZ when none is discarded) where allowed. Always verify payer-specific rounding before billing.
🔁 NDCs that bill under J0717 LEAST EXPENSIVE FIRST
4 NDCs map to J0717. Bill units = how many HCPCS units one package represents. Est. pay / pkg = payment limit ($3.444/unit) × that package's bill units.
| NDC (11-digit) | Drug | Labeler | Package | Strength | Bill units | Est. pay / pkg | NADAC / unit | Status | Source |
|---|---|---|---|---|---|---|---|---|---|
| 50474-0710-81 | Cimzia certolizumab pegol 200 mg/mL INJECTION, SOLUTION | UCB, | 3 CARTON in 1 BOX (50474-710-81) / 2 SYRI... | 200 mg/mL | 1,200 | $4,132.80 | $6,072.510 | ● Active | CMS ASP |
| 50474-0710-79 | Cimzia certolizumab pegol 200 mg/mL INJECTION, SOLUTION | UCB, | 2 SYRINGE, GLASS in 1 CARTON (50474-710-79... | 200 mg/mL | 400 | $1,377.60 | $6,094.020 | ● Active | CMS ASP |
| 50474-0700-62 | Cimzia certolizumab pegol KIT | UCB, | 2 KIT in 1 CARTON (50474-700-62) / 1 KIT... | — | 400 | $1,377.60 | — | ● Active | CMS ASP |
| 50474-0750-10 | Cimzia certolizumab pegol 200 mg/mL INJECTION, SOLUTION | UCB, | 1 SYRINGE, GLASS in 1 CARTON (50474-750-10... | 200 mg/mL | 200 | $688.80 | — | ● Active | CMS ASP |
NDC→HCPCS mappings come from the CMS ASP NDC-HCPCS crosswalk; additional DME MAC / DMEPOS mappings come from PDAC and are labeled separately. NADAC from CMS (weekly). “Status” reflects the product's marketing / obsolete flag in the NDC directory. Presence or absence here does not determine Medicare coverage. Linked NDCs open the full product page.
📊 Medicare utilization & spend CMS · PART B · 2026 (Q1)
Period
Total Part B spend
$79.11M
Claims
53,117
Beneficiaries
20,564
Spend / beneficiary
$3,847.06
Spend / claim
$1,489.37
Trend by period
Where J0717 ranks among Part B drugs · 2026 (Q1) · neighbors ±5
Total spending — #41 of 824
#36
OCTREOTIDE ACETATE E... J2353
$101.31M
#37
ACTEMRA(J3262) J3262
$99.7M
#38
KYPROLIS J9047
$88.51M
#39
INFLIXIMAB* J1745
$82.56M
#40
HIZENTRA J1559
$79.43M
#41
CIMZIA (2 PACK)* J0717
$79.11M
#42
SIMPONI ARIA J1602
$77.87M
#43
KRYSTEXXA J2507
$76.71M
#44
TEZSPIRE J2356
$75.17M
#45
NUCALA J2182
$74.59M
#46
CARVYKTI Q2056
$74.24M
Total claims — #47 of 824
#42
EUFLEXXA J7323
60,496
#43
SODIUM CHLORIDE(J703... J7030
59,637
#44
MYCOPHENOLIC ACID* J7518
57,045
#45
IODIXANOL(Q9966)* Q9966
56,735
#46
HEPLISAV-B 90739
54,586
#47
CIMZIA (2 PACK)* J0717
53,117
#48
LEQEMBI J0174
52,011
#49
EXPAREL J0666
51,998
#50
FAMOTIDINE J1308
51,954
#51
GAMMAGARD LIQUID J1569
49,707
#52
HYALGAN* J7321
48,959
Top Medicare Part B drugs by the selected metric. Click any drug to open its J-code page. Source: CMS Medicare Quarterly Part B Spending by Drug.
Full breakdown by period (2)
| Period | Total spend | Beneficiaries | Claims | $/beneficiary | $/claim |
|---|---|---|---|---|---|
| 2026 (Q1) | $79.11M | 20,564 | 53,117 | $3,847.06 | $1,489.37 |
| 2025 (Q1-Q4) | $362.19M | 26,276 | 231,093 | $13,784.11 | $1,567.30 |
Provider-administered (Part B) spend, calculated for the whole HCPCS code (CMS does not publish Medicare spend per individual NDC). Self-administered use is covered under Part D instead. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part B Spending by Drug (data.cms.gov), updated quarterly.
📈 Medicare Part B claims detail CMS PSPS · 2024
Calendar-year 2024 Medicare Part B fee-for-service activity for this HCPCS code, summed across all carriers, localities and specialties (CMS Physician/Supplier Procedure Summary). A “service” is one billed line/unit — not one claim — so counts run higher than claim counts.
Allowed charges
$322.71M
Medicare paid
$249.12M
Submitted services
80,515,306
Denial rate
1.3%
Allowed / service
$4.06
Submitted charges
$1.13B
Source: CMS Physician/Supplier Procedure Summary (PSPS), CY2024 — Medicare Part B carrier + DME fee-for-service claims (excludes Medicare Advantage). Figures are for the whole HCPCS code, which may cover uses beyond this drug. ⚠ CMS hides any figure covering fewer than 11 patients (a privacy rule), so totals — especially denials and low-volume codes — run a little low.
🗺️ Where J0717 is utilized CMS · BY PROVIDER · 2024
Medicare Part B services for this code by the rendering provider's state — 61,165,045 services across 47 states & territories in 2024 (CMS reports include DC and U.S. territories). Switch to per 100k to compare states fairly regardless of population. Hover or tap a state for its top ZIP codes.
Hover or tap a state to see its numbers + top ZIP codes.
Per-capita = services ÷ 2023 state population × 100,000 (so high-population states aren't automatically "hotter"). Counts reflect the provider's location, not the patient's. Providers with fewer than 11 patients are hidden by CMS for privacy, so totals run low and per-100k can be noisy in small states — read this as relative geography, not exact counts. Source: CMS Medicare Physician & Other Practitioners — by Provider and Service, 2024.
🗃️ Data sources & freshness
Every figure on this page is computed from public datasets. Here's what each section draws on and how current it is.
HCPCS code & descriptor
CMS HCPCS Level II code file
Loaded
Payment limit & billing unit
CMS Medicare Part B ASP Pricing File (quarterly)
Q3 2026 · as of 2026-08-20
NDC ↔ HCPCS crosswalk
CMS ASP NDC-HCPCS crosswalk
4 NDCs mapped
NADAC acquisition cost
CMS National Average Drug Acquisition Cost (weekly)
Available for mapped NDCs
Utilization & spend
CMS Part B Spending by Drug · PSPS · Physician & Other Practitioners
Latest data year 2026
Figures are estimates for reference and may lag the source files. Always verify against the current CMS files and your payer's policy before submitting claims.
⚠️ Practical billing caveats
- A crosswalk is not coverage. An NDC mapping or a published payment limit does not guarantee a payer will cover or pay this code. Check the specific plan's policy.
- Units ≠ milligrams. Bill the number of HCPCS units (dose ÷ the code's unit size), not the milligram dose. Use the calculator above.
- Discarded drug. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (and JZ when nothing is discarded) where the payer allows.
- Rounding & partial units. Many payers require whole units; round per the payer's policy, not automatically up.
- The code can cover more than this drug. Some HCPCS codes span multiple products or strengths — confirm the exact code for the product administered.
- Figures lag. ASP limits change quarterly and utilization data are released with a delay. Verify against the current CMS files before billing.
❓ J0717 billing FAQ
What is HCPCS code J0717?
J0717 is a HCPCS Level II J-code used to bill Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) under Medicare Part B and most medical (not pharmacy) benefits.
What is the billing unit for J0717?
One unit of J0717 represents 1 MG. Report the number of units equal to the dose administered divided by 1 MG.
How many units of J0717 should I bill?
Divide the dose administered by the code's unit size (1 MG) to get the number of billing units, then round per your payer's policy. The calculator on this page converts a dose into billing units and projects a full course.
How much does Medicare pay for J0717?
The Medicare Part B payment limit is $3.444 per unit (Q3 2026), based on ASP + 6%. After the 2% sequester the effective payment is about $3.375 per unit. Payment limits are revised quarterly.
Which NDCs bill under J0717?
4 NDCs currently map to J0717 in the CMS ASP NDC-HCPCS crosswalk. See the NDC crosswalk table above for each product, package, billing units and estimated reimbursement.
Does a crosswalk mean J0717 is covered?
No. An NDC-to-HCPCS crosswalk and a published payment limit do not guarantee coverage or payment. Coverage depends on the payer, the diagnosis and the site of care — always verify the current policy before billing.
For professional billing reference only — verify against the current CMS files before submitting claims.